沙利多胺通过调节BKCa通道,改善了大鼠中单克罗他林诱导的肺动脉高血压
Guo-Qing Lu1, Hong-Yan Sun1, Mei-Yang Xu1
1Department of Cardiovascular Medicine of the First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, 233000, PR China; Key Laboratory of Basic and Clinical Cardiovascular and Cerebrovascular Diseases, Bengbu Medical University, Bengbu, Anhui Province, 233004, PR China.
European journal of pharmacology
|July 27, 2025
概括
沙利德 (Sal) 通过恢复肺动脉光滑肌细胞 (PASMCs) 中的通道功能来保护肺动脉高血压 (PAH). 它抑制PKCα,促进血管扩张并改善PAH症状.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管研究研究心血管研究
- 细胞生物学 细胞生物学
背景情况:
- 肺动脉高血压 (PAH) 涉及肺动脉光滑肌细胞 (PASMCs) 中通道的功能障碍.
- 大导电激活通道 (BKCa) 在PASMC功能和PAH发展中发挥着关键作用.
研究的目的:
- 研究沙利德 (Sal) 对肺动脉高血压 (PAH) 的治疗作用.
- 在PAH的背景下,阐明Sal在PASMC中影响BKCa通道的机制.
主要方法:
- 已确立的PAH大鼠模型使用单克罗他林 (MCT) 和体外PASMC模型通过血小板衍生生长因子-BB刺激.
- 评估了Salidroside对右心室压力,肺血管重塑和PASMC电生理学的影响.
- 研究了PKCα在Salidroside对BKCa通道活性调节中的作用.
主要成果:
- 在MCT诱导的PAH大鼠中,沙利多治疗降低了右心室压力和肺血管重塑.
- 盐增加了BKCa通道蛋白表达,抑制了PASMC的增殖,促进了细胞亡,并改善了电生理学特征.
- 沙利德化物通过抑制PKCα激活了BKCa通道,导致K+流量增强,高极化和血管扩张.
结论:
- 沙利多胺通过恢复PASMC中的BKCa通道活性,有效地改善PAH.
- 萨尔的机制涉及抑制PKCα,这使PASMC增殖和亡之间的平衡正常化.
- 沙利德化物为治疗肺动脉高血压提供了一个有希望的治疗策略.
相关概念视频
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
259
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
259
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
927
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
927
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
510
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510
01:23Antihypertensive Drugs: Vasodilators
644
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
644
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
773
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
773
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
225
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
225